# CancerNetwork

> CancerNetwork - Healthcare Publication

- Base URL: https://www.cancernetwork.com
- Generated: 2026-07-04T11:40:46.549Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.cancernetwork.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.cancernetwork.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.cancernetwork.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.cancernetwork.com/robots.txt](https://www.cancernetwork.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Around the Practice](https://www.cancernetwork.com/around-the-practice)
- [Between the Lines](https://www.cancernetwork.com/between-the-lines)
- [Breaking Barriers](https://www.cancernetwork.com/breaking-barriers)
- [Clinical](https://www.cancernetwork.com/clinical)
- [Clinical Consult](https://www.cancernetwork.com/clinical-consult)
- [Conference](https://www.cancernetwork.com/conference)
- [Face-Off](https://www.cancernetwork.com/face-off)
- [From All Angles](https://www.cancernetwork.com/from-all-angles)
- [Frontline Forum](https://www.cancernetwork.com/frontline-forum)
- [Global Bulletin](https://www.cancernetwork.com/global-bulletin)
- [Hero](https://www.cancernetwork.com/hero)
- [Integrative Care](https://www.cancernetwork.com/integrative-care)
- [Media](https://www.cancernetwork.com/media)
- [Meeting of the Minds](https://www.cancernetwork.com/meeting-of-the-minds)
- [Men's Health](https://www.cancernetwork.com/mens-health)
- [News](https://www.cancernetwork.com/news)
- [OncView](https://www.cancernetwork.com/k-cast)
- [Podcasts](https://www.cancernetwork.com/podcasts)
- [Publications](https://www.cancernetwork.com/journals)
- [Quizzes](https://www.cancernetwork.com/resources/quizzes)
- [Readout 360](https://www.cancernetwork.com/readout-360)
- [Resources](https://www.cancernetwork.com/resources)
- [Roles](https://www.cancernetwork.com/roles)
- [The Bispecifics Network](https://www.cancernetwork.com/the-bispecific-network)
- [Training Academy](https://www.cancernetwork.com/training-academy)
- [Treatment Algorithms with the Oncology Brothers](https://www.cancernetwork.com/treatment-algorithms-with-the-oncology-brothers)
- [Tumor Board Series](https://www.cancernetwork.com/tumor-board-series)
- [Video Series](https://www.cancernetwork.com/video-series)
- [Videos](https://www.cancernetwork.com/videos)
- [Webinars](https://www.cancernetwork.com/webinars)
- [Year in Review](https://www.cancernetwork.com/year-in-review)

## Featured Content

- [28 A Cost-Utility Analysis Comparing Indocyanine Green to Methylene Blue Dye in Axillary Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer](https://www.cancernetwork.com/view/28-a-cost-utility-analysis-comparing-indocyanine-green-to-methylene-blue-dye-axillary-lymphatic-mapping-slnb): A decision tree cost-utility analysis found ICG more cost-effective than methylene blue for SLNB in breast cancer (ICER $4,044/QALY), with Monte Carlo...
- [29 A Demonstration of Opportunity Cost in Surgical Delays When Using Needle Localization Versus MOLLI Localization in Breast Surgery](https://www.cancernetwork.com/view/29-a-demonstration-of-opportunity-cost-in-surgical-delays-when-using-needle-localization-versus-molli-localization-in-breast-surgery): Compared with wire-guided needle localization, MOLLI localization was associated with shorter median OR delays, fewer overall delays, and an estimated...
- [Long-Term COMMANDS Data Reinforce Luspatercept as Frontline MDS Therapy](https://www.cancernetwork.com/view/long-term-commands-data-reinforce-luspatercept-as-frontline-mds-therapy): Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discuss how long-term COMMANDS data support the use of luspatercept.
- [Elucidating CAR T-Cell Candidacy for Diffuse Large B-Cell Lymphomas](https://www.cancernetwork.com/view/elucidating-car-t-cell-candidacy-for-diffuse-large-b-cell-lymphomas): Experts focused on lymphoma cellular therapy convened to discuss CAR T-cell candidacy and practical barriers to access for patients with DLBCL.
- [3 Things You Should Know About Targeted Therapies for Gliomas](https://www.cancernetwork.com/view/3-things-you-should-know-about-targeted-therapies-for-gliomas): Learn how to evaluate the data for recent advancements in immunotherapy, targeted therapy, and other modalities in the treatment of patients with glio...
- [Mezigdomide Drives 41% ORR in Triple-Class Refractory Multiple Myeloma](https://www.cancernetwork.com/view/mezigdomide-drives-41-orr-in-triple-class-refractory-multiple-myeloma): Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, explain how mezigdomide’s complete cereblon E3 ligase engagement overcomes IMiD resistance in hea...
- [Relapsed/Refractory Multiple Myeloma: Clinical Development and Early Experience With Talquetamab](https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-clinical-development-and-early-experience-with-talquetamab): Dr. Ajai Chari and Dr. Rahul Banerjee review the clinical development of talquetamab in relapsed/refractory multiple myeloma (RRMM), focusing on key f...
- [Relapsed/Refractory Multiple Myeloma: Expanding Beyond BCMA With GPRC5D Targeting](https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-expanding-beyond-bcma-with-gprc5d-targeting): Dr. Ajai Chari and Dr. Rahul Banerjee discuss the growing need for therapeutic targets beyond BCMA in relapsed/refractory multiple myeloma (RRMM) and...
- [30 Accuracy and Operational Efficiency of the MOLLI Marker Compared to Needle Localization in Breast Surgery](https://www.cancernetwork.com/view/30-accuracy-and-operational-efficiency-of-the-molli-marker-compared-to-needle-localization-in-breast-surgery): Early adoption of the MOLLI wireless localization system demonstrated a rapid learning curve, fewer missed biopsy clips, and a significant reduction i...
- [31 E-Strain Elastography as an Adjunct of Breast Ultrasound: Impact on Biopsy Decision-Making](https://www.cancernetwork.com/view/31-e-strain-elastography-as-an-adjunct-of-breast-ultrasound-impact-on-biopsy-decision-making): In 161 biopsied breast masses, malignant lesions showed significantly higher E-strain ratios than benign lesions (3.51 vs 1.93), with progressive incr...

## Feeds and Indexes

- [RSS Feed](https://www.cancernetwork.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.cancernetwork.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.cancernetwork.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.cancernetwork.com/authors): Browse all contributors and their published work